Risk factors
Biocryst Pharmaceuticals (BCRX) risk factors
Item 1A of every Biocryst Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks16 new8 dropped17 reworded
Merger integration risks regarding Astria and its product candidate navenibart dominate the newly added disclosures. New disclosures address the path to sustained profitability after achieving first annual net income in 2025. Risks related to generic and biosimilar competition are expanded.
Filed Feb 26, 2026 - FY2024 10-K risk factors55 risks
Operating losses and capital needs dominate the risk profile, alongside commercialization hurdles for ORLADEYO and RAPIVAB.
Filed Feb 25, 2025